Skip to content

Homoeopathic treatment of tooth problems

A randomized, double-blind, placebo-controlled trial of individualized homoeopathic medicines in addition to standard care in chronic periodontitis in adults

Status
Recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/03/050348
Enrollment
128
Registered
2023-03-03
Start date
Unknown
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K053- Chronic periodontitis

Interventions

Intervention1: Individualized homoeopathic medicines in centesimal potencies plus standard care: Intervention is planned as administering the indicated homoeopathic medicines in centesimal potencies (
dosage and repetition depending upon the individual requirement of the cases. Patients will be advised to refrain from handling the globules or from eating, drinking, smoking or brushing teeth within
dosage and repetition will be decided depending upon the individual requirement of the cases. All sundry items will be procured from a Good Manufacturing Practice (GMP) certified firm. All the patien

Sponsors

D N De Homoeopathic Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with chronic periodontitis, as diagnosed by the periodontitis screening and recording (PSR) (ICD10 code: K05.30), symptoms persisting for 3 months or more, as assessed by: a) Gingival plaque (score up to 3) b) Altered gingival margins (rolled, flattened, recessions) c) Bleeding on probing (BOP; score up to 3) d) Periodontal probing depth (PPD; up to 4-5.5mm) e) Clinical attachment loss (CAL; moderate 3 to 4 mm) 2. Patients having at least 22 teeth present 3. Age 18 to 65 years 3. Participants of either sex 4. Literate: ability to read English, Hindi and/or Bengali (Illiterate people will be interviewed by the investigators maintaining adequate privacy to fill up the questionnaires). 5. Providing with written informed consent voluntarily

Exclusion criteria

Exclusion criteria: 1. Severe form of chronic periodontitis (more than 5 mm CAL) or aggressive periodontitis 2. Patients who have undergone nonsurgical periodontal treatment (NSPT) within 6 months. 3. Antibiotics and steroids therapy for periodontitis or gingivitis or any other similar conditions in the last month 4. Patients having orthodontic appliances 5. Cases having severe oral inflammation unrelated to periodontal conditions 6. Cases requiring immediate tooth extraction 7. Vulnerable population - unconscious, non-ambulatory, differently abled, terminally ill or critically ill patients, mentally incompetent people. 8. Diagnosed cases of unstable mental or psychiatric illness, infectious disease (e.g., tuberculosis) or other uncontrolled or life-threatening illness affecting quality of life or any organ failure 9. Tobacco chewing and/or smocking, alcoholism, and/or any other form(s) of substance 10. Self-reported immune-compromised state e.g., HIV 11. Pregnant and puerperal women, lactating mothers 12. Undergoing homoeopathic treatment for chronic disease within the last 6 months. 13. Simultaneously participations in any other clinical trials.

Design outcomes

Primary

MeasureTime frame
Periodontal probing depth (PPD)Timepoint: Baseline, and every month, up to 3 months

Secondary

MeasureTime frame
Bleeding on probing (BOP)Timepoint: Baseline, and every month, up to 3 months;C-reactive protein (CRP)Timepoint: Baseline and after 3 months;Clinical attachment loss (CAL)Timepoint: Baseline, and every month, up to 3 months;Oral Health Impact Profile (OHIP-14) questionnaireTimepoint: Baseline, and every month, up to 3 months;Visible plaque index (VPI)Timepoint: Baseline, and every month, up to 3 months

Countries

India

Contacts

Public ContactArpita Basu

D N De Homoeopathic Medical College & Hospital

drarpitasen@gmail.com9830273374

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026